reaching more and more people around the globe. In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow. Our high rate of investment in pioneering science, backed up by strong alliances with professional partners, allows us to bring our neurology and immunology drugs to hundreds of new patients every day and across the globe. Our planned sustainable growth will come from ground-breaking science and from bringing added value to patients, as well as being the preferred partner to all our other stakeholders. It's summed up by UCB's twin motivations, Inspired by patients. Driven by science. Caring as a company, and as individuals. Our Corporate Societal Responsibility program rests on two strategic pillars: Planet, aimed at reducing our ecological footprint across the globe and Patients, focused on helping people living with epilepsy in developing countries. To support our CSR program, we have put in place our UCB Societal Responsibility Fund. The UCB Fund focuses on projects that support epilepsy patients and their families in underprivileged areas of the world. Everywhere, our colleagues - from Europe to China and from the U.S. to Australia - proactively volunteer for good causes in their community. The funds raised in such community activities can then be donated towards the UCB Fund. Our colleagues have proven time again that caring for patients goes beyond our day-to-day jobs. To learn more about the UCB Societal Responsibility Fund, please visit www.ucb.com/our-company/csr/csr-Fund.
In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow. Our high rate of investment in pioneering science, backed up by strong alliances with professional partners, allows us to bring our neurology and immunology drugs to hundreds of new patients every day and across the globe. Our planned sustainable growth will come from ground-breaking science and from bringing added value to patients, as well as being the preferred partner to all our other stakeholders. It’s summed up by UCB’s twin motivations, Inspired by patients. Driven by science.

Our Corporate Societal Responsibility program rests on two strategic pillars: Planet, aimed at reducing our ecological footprint across the globe and Patients, focused on helping people living with epilepsy in developing countries.

To support our CSR program, we have put in place our UCB Societal Responsibility Fund. The UCB Fund focuses on projects that support epilepsy patients and their families in underprivileged areas of the world. Everywhere, our colleagues - from Europe to China and from the U.S. to Australia - proactively volunteer for good causes in their community. The funds raised in such community activities can then be donated towards the UCB Fund. Our colleagues have proven time again that caring for patients goes beyond our day-to-day jobs.

To learn more about the UCB Societal Responsibility Fund, please visit www.ucb.com/our-company/csr/csr-Fund
Meeting patients’ unmet needs

Just because our medicines treat thousands of people around the world doesn’t mean our job is done. For us, it’s vital that we listen to the constantly evolving needs of patients and their families. Working with physicians and healthcare professionals, we are engaging more with patients in every step of their healthcare journey to find new solutions. What matters most is how they feel in their everyday life as they progress on their healthcare journey. Because we’re not just treating a disease. We’re caring for individual people.

Patients inspire us to bring them value through more cutting-edge science, more innovative drugs, and more practical solutions – so that they, and their caretaker, can get on with their lives.

Today we help people living with...

**Immune-related diseases**
- Rheumatoid arthritis
- Psoriatic arthritis
- Axial spondyloarthritis (including ankylosing spondylitis)
- Crohn’s disease

**Neurological diseases**
- Epilepsy
- Parkinson’s disease
- Restless legs syndrome

Looking ahead...

We hope that new UCB medicines will help people living with diseases such as:
- Bone loss disorders
- Epilepsy
- Parkinson’s disease

Connecting with patients every step of the way

We have a shared ambition to transform the lives of people living with severe diseases.

Everything we do starts with one simple question: “how will this create value for people living with severe diseases?”

Connecting with patients every step of the way

UCB: reaching more and more people around the globe

In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow. Our high rate of investment in pioneering science, combined with our focus on strong alliances and an unwavering commitment to improving lives, means that UCB continues to develop transformative medicines and immunology drugs to hundreds of new patients every day and across the globe.

Our planned sustainable growth will come from groundbreaking science and from bringing added value to patients, as well as being the preferred partner to all our other stakeholders. It’s summed up by UCB’s twin motivations: Inspired by patients. Driven by science.

Hundreds of thousands of new patients benefiting from new UCB medicines in the coming years.
We have a shared ambition
to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world.

Everything we do starts with one simple question: “how will this create value for people living with severe diseases?”

Continuously advancing science

With seriousness about science and this is what drives us to create a pipeline of breakthrough medicines that will make a real difference to peoples lives.

How do we do it? We recognize our key asset: our pioneering expertise in both small and large molecules, we prioritize clearly. We make robust decisions. All of which enables us to rapidly advance promising molecules into innovative therapies.

With no patent expiries on the horizon, and a strong late-stage pipeline, we are now entering an exciting new era at UCB driven by scientific excellence.

UCB’s own breakthrough

For many years, following our founding by Emannuel Janssen in 1928, UCB (originally Union Chimique Belge) was renowned for its diverse expertise across pharmaceuticals, chemicals and films.

By the 80s, we had begun our journey into biotechnology. The 80s and 90s saw the birth of a number of our blockbuster drugs. And over the last decade we have made a series of visionary leaps and agile changes that have transformed UCB into a leading global biopharmaceutical company.

We are now building on our strong heritage in research and development. We have a rich and innovative pipeline that focuses on the needs of patients to better understand their clinical, economic, social and personal needs. What matters most is how they feel in their everyday life as they progress on their healthcare journey.

Because we're not just treating a disease, but treating the person. We care about their unmet needs. For us, it's vital that we listen to the world doesn't mean our job is done. For us, it's vital that we listen to the patient, and their carers, can get on with their lives.

Connecting with patients

• Crohn’s disease

• Ankylosing spondylitis

• Rheumatoid arthritis

A rich and innovative pipeline that focuses on the needs of people living with severe diseases.

That's what drives us.

We are now building on our strong heritage in research and development. We have a rich and innovative pipeline that focuses on the needs of patients – both today and in the future.

We believe sharing knowledge and expertise is essential for the rapid growth of scientific understanding. And that innovative therapies to patients require intense collaboration.

That's why we have teamed up with other leading companies across the pharmaceutical industry. We have also developed a strong global network of internationally renowned clinicians and academia, who collaborate with us in our drug discovery activities.

We, in turn, are happy to share our own skills and expertise with professional partners, allowing us to bring our neurology expertise to the forefront of science.

Compliance always

Our work has a direct impact on human lives and we remain robustly compliant in all we do. We run rigorous internal training programs, we follow the strictest regulatory stan-

dards for drug development and manufacturing. When it comes to compliance, we operate a zero-tolerance policy.

Stronger together

We believe sharing knowledge and expertise is essential for the rapid growth of scientific understanding. And that innovative therapies to patients require intense collaboration.

That's why we have teamed up with other leading companies across the pharmaceutical industry.

We have also developed a strong global network of internationally renowned clinicians and academia, who collaborate with us in our drug discovery activities.

We, in turn, are happy to share our own skills and expertise with professional partners, allowing us to bring our neurology expertise to the forefront of science.

UCB: reaching more and more people around the globe

In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow. Our high rate of investment in pioneering science, new drug development and the management of neurology and immunology disorders has increased and has created a pipeline of innovative medicines.

In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow. Our high rate of investment in pioneering science, new drug development and the management of neurology and immunology disorders has increased and has created a pipeline of innovative medicines.

We are now building on our strong heritage in research and development. We have a rich and innovative pipeline that focuses on the needs of patients – both today and in the future.

We believe sharing knowledge and expertise is essential for the rapid growth of scientific understanding. And that innovative therapies to patients require intense collaboration.

That's why we have teamed up with other leading companies across the pharmaceutical industry.

We have also developed a strong global network of internationally renowned clinicians and academia, who collaborate with us in our drug discovery activities.

We, in turn, are happy to share our own skills and expertise with professional partners, allowing us to bring our neurology expertise to the forefront of science.

Compliance always

Our work has a direct impact on human lives and we remain robustly compliant in all we do. We run rigorous internal training programs, we follow the strictest regulatory stan-

dards for drug development and manufacturing. When it comes to compliance, we operate a zero-tolerance policy.

Stronger together

We believe sharing knowledge and expertise is essential for the rapid growth of scientific understanding. And that innovative therapies to patients require intense collaboration.

That's why we have teamed up with other leading companies across the pharmaceutical industry.

We have also developed a strong global network of internationally renowned clinicians and academia, who collaborate with us in our drug discovery activities.

We, in turn, are happy to share our own skills and expertise with professional partners, allowing us to bring our neurology expertise to the forefront of science.

Compliance always

Our work has a direct impact on human lives and we remain robustly compliant in all we do. We run rigorous internal training programs, we follow the strictest regulatory stan-
dards for drug development and manufacturing. When it comes to compliance, we operate a zero-tolerance policy.

Pushing the boundaries of science
We have a shared ambition

to transform the lives of people living with severe diseases.

We focus on neurology and immunology disorders – putting patients at the center of our world.

Everything we do starts with one simple question: “how will this create value for people living with severe diseases?”

We’re caring for individual people. We’re caring for individual people.

Connecting with patients

We’re caring for individual people. We’re caring for individual people.

Making a difference

With more than 7,500 staff, UCB offers an exciting working environment where initiative can flourish and those with a can-do attitude can thrive.

Every colleague is invited to make their mark, to contribute to our relentless journey, and to become a part of the company’s evolution. And we continue to exceed expectations.

Hundreds of new colleagues from health care and business backgrounds have joined us within the last two years. They bring with them a dynamic energy, fresh perspectives, and new ideas.

Developing and connecting talent

Scientific excellence, innovation – co-creation, agility – innovating the way we do things – and of course a passion for bringing value to patients in all our areas of therapy and geography – we work constantly on finding the right people.

At the same time, we ensure every UCB colleague has the tools and environment to engage effectively in the work we do. Whatever it is we are based on, and no matter what role we play in the company, we believe every one of us can have an impact across our organisation.

From early research right through to manufacturing and sales, we all pull together to achieve transformative solutions for patients and their families. In fact, in yearly sales, we all pull together to achieve transformative solutions for patients and their families. In fact, in yearly sales, we all pull together to achieve transformative solutions for patients and their families. In fact, in yearly sales, we all pull together to achieve transformative solutions for patients and their families.

In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow.

Our high rate of investment in pioneering science, world-class facilities, and expanding our clinical and commercial reach enables us to bring more people around the globe.

In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow. Our high rate of investment in pioneering science, world-class facilities, and expanding our clinical and commercial reach enables us to bring more people around the globe. In recent years we have extended our presence to more global regions and patients than ever before. And we continue to grow.